Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Current understanding of cardiovascular autonomic dysfunction in multiple sclerosis.
Journal: Heliyon
Published: May 30, 2024
Aldehyde Dehydrogenase 2 Activator Augments the Beneficial Effects of Empagliflozin in Mice with Diabetes-Associated HFpEF.
Journal: International journal of molecular sciences
Published: August 04, 2022
Effects of intracardiac delivery of aldehyde dehydrogenase 2 gene in myocardial salvage.
Journal: Gene therapy
Published: February 22, 2022
Diabetic Aldehyde Dehydrogenase 2 Mutant (ALDH2*2) Mice Are More Susceptible to Cardiac Ischemic-Reperfusion Injury Due to 4-Hydroxy-2-Nonenal Induced Coronary Endothelial Cell Damage.
Journal: Journal of the American Heart Association
Published: September 06, 2021
4-Hydroxy-2-nonenal, a lipid peroxidation product, as a biomarker in diabetes and its complications: challenges and opportunities.
Journal: Free radical research
Published: December 18, 2020
4-Hydroxy-2-nonenal attenuates 8-oxoguanine DNA glycosylase 1 activity.
Journal: Journal of cellular biochemistry
Published: December 18, 2019
Aldehyde Dehydrogenase (ALDH) 2 in Diabetic Heart Diseases.
Journal: Advances in experimental medicine and biology
Published: August 02, 2019
Precision medicine approach: Empagliflozin for diabetic cardiomyopathy in mice with aldehyde dehydrogenase (ALDH) 2 * 2 mutation, a specific genetic mutation in millions of East Asians.
Journal: European journal of pharmacology
Published: April 09, 2018
Last Updated: 09/26/2026